As Founder of Ochre, and previously CSO, Quin has been driving the company’s innovative approach to late-stage liver disease – developing potential new therapeutics to target disease progression. Quin will now lead the company in the next phase of its ambitions: progressing new drug candidates towards the clinic.
With two major pharma partnership deals with GSK and Boehringer Ingelheim underway, Ochre is identifying disease modifying targets and RNA therapies that have the potential to reverse fibrosis, cirrhosis and other end-stage liver diseases. Ochre is driving progress in a space that has long lacked options for patients by use of its world leading liver perturbation atlases.
Eliot Forster, Ph.D, Chair of the Board of Directors at Ochre said: “I’m delighted to announce Quin’s appointment as CEO of Ochre. Quin’s appointment is excellent news for Ochre, its investors and the treatment of liver diseases. I’m personally delighted to continue to work with Quin and look forward to even greater progress under his leadership.”
Quin has dedicated his life’s work to finding breakthrough treatments for late stage liver disease. With his medical training, and degrees in genetics and mathematics from Oxford and Cambridge Universities, Quin founded his first drug discovery company in liver genomics 20 years ago. He’s since made significant steps in researching the genetic drivers of chronic liver disease and pioneering novel treatments.
Now, at Ochre, Quin oversees the world’s largest perfused liver lab in New York, where the company is using human models to make AI-incorporated drug discovery a clinical reality.
Quin Wills, Founder and CEO at Ochre Bio, said: “We started Ochre almost six years ago with a simple mission: to rewrite the future for people living with chronic liver disease. I could not be more thrilled to now be steering our therapies towards the clinic. Getting medicines to patients has been a deeply personal journey of twenty years in liver research.”